静脉基因治疗改善Sandhoff病猫模型的生存期与临床结局
本研究在症状前1月龄Sandhoff病猫模型中测试静脉注射双顺反子AAV基因治疗。未治疗猫存活4.3±0.2月,低剂量与高剂量治疗猫分别存活8.3±1.2月与12.4±2.7月,并见震颤预防、CNS损伤标志物降低及GM2蓄积剂量依赖性减少,支持静脉给药基因治疗的转化潜力。
要点
- 静脉AAV基因治疗在症状前SD猫中呈剂量依赖性延长生存期。
- 治疗改善震颤、降低CNS损伤标志物并部分纠正影像与病理异常。
- 高剂量组见肝脏弹性成像改善及Hex活性升高、GM2蓄积减少。
核心结论
- 静脉递送AAV基因治疗在SD猫模型中呈剂量依赖性恢复Hex活性并保留临床指标,支持向SD患者转化。
研究设计与样本
- 在1月龄症状前SD猫模型中经静脉给予双顺反子AAV载体基因治疗,设未治疗对照及低、高剂量治疗组。
主要发现
- 未治疗SD猫存活4.3±0.2月,低剂量组存活8.3±1.2月,高剂量组存活12.4±2.7月。
- 治疗预防明显全身震颤,并降低脑脊液与血清CNS损伤标志物。
- MRI与波谱显示结构病理与代谢异常部分正常化,高剂量组肝脏超声弹性成像改善。
- 见剂量依赖性GM2蓄积减少与Hex活性升高,伴神经炎症细胞减少及髓鞘缺陷部分纠正。
临床怎么用
- 结果提示静脉AAV基因治疗可作为SD的潜在转化策略,尚需临床研究验证。
局限性
- 研究为SD猫模型且于症状前1月龄治疗,结论外推至患者需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sandhoff disease (SD) is a fatal neurodegenerative disorder caused by the absence of β-N-acetylhexosaminidase (Hex) and subsequent accumulation of GM2 ganglioside in lysosomes. Previous studies have led to the development of an adeno-associated virus (AAV) vector-delivered gene therapy for children with GM2 gangliosidosis in both expanded access and phase 1/2 clinical trials through intrathalamic and cerebrospinal fluid-based delivery. This study investigated intravenous delivery of a bicistronic AAV vector-based gene therapy that has not yet been tested in clinical trials to a feline model of SD, treated presymptomatically at 1 month of age. Whereas untreated SD cats lived to 4.3 ± 0.2 months, SD cats treated with low or high doses of the gene therapy lived to 8.3 ± 1.2 or 12.4 ± 2.7 months, respectively. In-life assessments revealed a clinical benefit of AAV treatment, with marked improvements seen in the prevention of overt full-body tremors; cerebrospinal fluid and serum markers of central nervous system damage were also reduced. Magnetic resonance imaging and spectroscopy indicated that the structural pathology and metabolite abnormalities seen in untreated SD cats were partially normalized by treatment. Ultrasound elastography showed improvement in the livers of cats in the high-dose treatment group. Dose-dependent reductions of GM2 ganglioside storage and increases in Hex activity were documented, associated with reduced neuroinflammatory cell populations and partial correction of myelin deficits. These data support the dose-dependent efficacy of intravenous-delivered gene therapy for restoration of Hex activity and preservation of clinical metrics, supporting potential for translation to patients with SD.
引用
- Maguire AS, Ta NL, Gross AL, et al. Intravenous gene therapy improves life span and clinical outcomes in a feline model of Sandhoff disease. Sci Transl Med. 2026. PMID: 42715347. doi:10.1126/scitranslmed.adx2447
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。